As a hospital executive, head of the radiotherapy department, radiation oncologist, medical physicist or radiotherapist, you may wonder if adding proton therapy treatment to your radiation oncology department can increase your hospital’s attractivity, improve cancer patient experience, and contribute to talent attraction and retention. ​

Prof. Barbara Alicja Jereczek-Fossa is Chair of Radiation Oncology at the European Institute of Oncology (IEO) in Milan and full Professor at the University of Milan, in Italy. She was elected President of the European Society for Radiotherapy and Oncology (ESTRO) in 2024 and her term is set to begin in 2026. ESTRO’s mission is to reinforce radiation oncology as a core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it. Prof. Jereczek-Fossa, a highly respected radiation oncologist, brings decades of clinical experience, institutional leadership at the IEO, and a powerful vision for expanding access to precision therapies like proton therapy worldwide. This article highlights her view on proton therapy and the future of precision cancer care. 

Find out how ProteusONE at IEO Milan combines precision, patient comfort, and future-ready technology to set new standards in cancer care.